All Stories

CDC’s ‘Wild to Mild’ flu vaccine campaign muzzled amid ...

A popular awareness campaign now in its second year that encouraged people to ge...

Regulatory tracker: BMS' Breyanzi wins NICE backing in ...

In this tracker, Fierce Pharma is recording the regulatory progress of in-market...

FDA hits pair of Indian API makers with warning letters...

Jagsonpal Pharmaceuticals and Tyche Industries, both makers of APIs based in Ind...

AstraZeneca pays $160M for FibroGen's China unit, regio...

AstraZeneca is paying $160 million for FibroGen’s Chinese business, giving the U...

Genentech, Novartis join forces to raise awareness of f...

Genentech and Novartis have teamed up with FARE to enhance the safety of childre...

AstraZeneca pays $160M for Fibrogen's China unit, regio...

AstraZeneca is paying $160 million for Fibrogen’s Chinese business, giving the U...

PhRMA leaders prepare to meet with Trump as new chair A...

Ahead of a meeting with President Donald Trump, trade group the Pharmaceutical R...

Bristol Myers Squibb notches overall survival win with ...

Bristol Myers Squibb has bolstered its case for Opdivo to be used as a preoperat...

Ionis marks 'milestone event' of Tryngolza launch with ...

To support the launch of Tryngolza, which is approved to treat adults with famil...

Ionis marks ‘milestone event’ of Tryngolza launch with ...

To support the launch of Tryngolza, which is approved to treat adults with famil...

Argenx banks on key prefilled syringe approval for Vyvg...

As argenx continues to rise to profitability based on the strength of its indica...

FDA disrupts Harmony's expansion dreams for excessive s...

The agency responded to Harmony's bid for an idiopathic hypersomnia nod for exce...

After high-profile pledge to secure confirmation, RFK J...

After making a pledge on vaccines to Sen. Bill Cassidy during his confirmation p...

Novartis, Roche grant CEO pay raises for 2024 as sales ...

After Novartis and Roche grew their sales last year, the Swiss pharma giants are...

Bristol Myers Squibb notches overall survival win with ...

Bristol Myers Squibb has bolstered its case for Opdivo to be used as a pre-opera...

Novartis pumps $7.5M into push to save 100,000 lives fr...

Novartis has committed $7.5 million to an initiative aiming to save 100,000 live...

Amid Merck supply squeeze, ImmunityBio and Serum Instit...

The FDA has authorized ImmunityBio’s expanded access program to bring alternativ...

Stock stagnation prompts a 16% pay cut for AstraZeneca ...

Despite AstraZeneca’s revenue growing 18% in 2024, the pay package for CEO Pasca...

Bavarian Nordic catches up to rival Valneva with broad ...

Valneva may have won the chikungunya vaccine race with its world-first approval,...

As BMS-paired triplet misses survival mark in kidney ca...

While Exelixis has abandoned a plan to seek an FDA approval for a combination of...

FDA signs off on Sanofi's insulin biosimilar, the first...

The FDA has given a thumbs up to Sanofi’s Merilog as the first biosimilar substi...

Regulatory tracker: Merck's Welireg wins 2 European app...

In this tracker, Fierce Pharma is recording the regulatory progress of in-market...

ICU Medical recalls potassium chloride IV bags over lab...

ICU Medical has voluntarily recalled two lots of potassium chloride intravenous ...

Argenx puts marketing muscle behind CIDP launch with Vy...

Argenx is urging patients to “Live Vyvidly.” The biotech put the message out in ...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.